Rib-X's skin infection drug enters late-stage study

05/17/2013 | Pharmaceutical Business Review Online

Rib-X Pharmaceuticals initiated a late-stage trial to assess the efficacy of a Captisol-enabled IV formulation of delafloxacin in patients with acute bacterial skin and skin structure infections. The trial triggered the payment of a $500,000 milestone fee to partner Ligand Pharmaceuticals.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC